| Name | Title | Contact Details |
|---|
TRUE crafts naturally comfortable gear that transcends the links. Using only the finest materials, our shoes protect you from the elements and help you #enjoythewalk. As a collective we aim to inspire each other to achieve camaraderie, wellness and purpose in the pursuit of par.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Exploring Opportunities in the Electric Vehicle Space.
Pendrick Capital Partners is one of the largest HEALTHCARE debt buyers in the USA providing additional revenue streams to all our clients. Our management team is comprised of industry veterans with over 80 years of combined knowledge. We bring core expertise to all consumer debt segments in our underwriting and servicing processes. We hold ourselves to the highest standards and take pride in our business relationships. Our commitment to customer service is unmatched in the industry, just ask for our references. The sale of aged A/R among HEALTHCARE providers has become much more mainstream over the last 10 years. During the last 3 years, Pendrick Capital Partners has purchased over 55 million accounts with a face value of over $16 billion. These portfolios represent patient accounts at ER physician groups, ambulance companies and hospitals. The desire of providers to implement a profitable, compliant, and sensible solution to their revenue cycle challenges and cash acceleration needs has never been greater. With the right partner, the impact of selling should be no different than the impact of using contingency collection agencies to recover delinquent accounts. In many cases, clients have informed us that this practice has enhanced overall collections, as it creates an expectation of payment within their patient bases. Pendrick Capital Partners recognizes the important role that physicians, clinics and hospitals play in local communities and conducts its business with the highest degree of professionalism and respect for patients and clients. Careful due diligence helps us understand an organization`s unique needs and ensures that our tailored collection efforts meet our clients expectations prior to starting a relationship. We do not resell accounts and strongly recommend that any healthcare provider who is concerned about patient and community relations makes a no-resale provision a non-negotiable part of its business agreement with any debt buyer.